Lesofavumab
- CAS No.
- 1807960-57-1
- Chemical Name:
- Lesofavumab
- Synonyms
- Lesofavumab;Research Grade Lesofavumab;Research Grade Lesofavumab (DVV03805)
- CBNumber:
- CB98081024
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | J8O0SI025W |
Lesofavumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0628953 | Lesofavumab 98.27% | 1807960-57-1 | 1mg | $325 | 2026-06-04 | Buy |
| ChemScene | CS-0628953 | Lesofavumab 98.27% | 1807960-57-1 | 5mg | $845 | 2026-06-04 | Buy |
| ChemScene | CS-0628953 | Lesofavumab 98.27% | 1807960-57-1 | 10mg | $1354 | 2026-06-04 | Buy |
| ApexBio Technology | BA2024 | Lesofavumab | 1807960-57-1 | 1mg | $270 | 2026-05-06 | Buy |
| ApexBio Technology | BA2024 | Lesofavumab | 1807960-57-1 | 5mg | $702 | 2026-05-06 | Buy |
Lesofavumab Chemical Properties, Uses, Production
Uses
Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody[1].
in vivo
Lesofavumab (46B8; 15 mg/kg; i.v.; single dose) is able to protect mice against lethal challenge of the mutant influenza B virus[2].
| Animal Model: | DBA/2J mice, B/Wisconsin/1/2010, B/Brisbane/60/2008, B/Victoria/504/2000, B/Russia/1/1969 or B/Massachusetts/3/1966 infection model[2] |
| Dosage: | 15 mg/kg |
| Administration: | Intravenous administration, single dose, 24, 48 or 72h post infection |
| Result: | Treatment at 24 and 48 h post infection resulted in 100% protection, with the only exception of mice infected with B/Russia/1/1969 that showed a 60% protection when treatment commenced at 48h. Even when given at 72h post infection, 48B8 was highly efficacious resulting in 100% protection against the B/Brisbane/60/2008, B/Victoria/504/2000 and B/Massachusetts/3/1966 strains, 75% protection against B/Wisconsin/1/2010 and 50% protection against B/Russia/1/1969. |
References
[1] Rao GK, et al. In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection. Toxicol Sci. 2019 Jun 1;169(2):409-421. DOI:10.1093/toxsci/kfz053
[2] Chai N, et al. A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun. 2017 Jan 19;8:14234. DOI:10.1038/ncomms14234
Lesofavumab Preparation Products And Raw materials
Raw materials
Preparation Products
Lesofavumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
| Changsha Fuzhen Biotechnology Co.，LTD | 15111215862 18229892877 | 3062105966@qq.com | China | 5568 | 58 |
| Wanxin Biotechnology (Jiaxing) Co., LTD | 0573-83568680 18057391398 | 3956524501@qq.com | China | 1441 | 58 |
